These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15069180)

  • 1. Sympathetic hyperactivity in chronic kidney disease.
    Blankestijn PJ
    Nephrol Dial Transplant; 2004 Jun; 19(6):1354-7. PubMed ID: 15069180
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Remme WJ
    Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympathetic overactivity in hypertensive patients with chronic renal disease.
    Remuzzi G
    N Engl J Med; 1999 Apr; 340(17):1360-1. PubMed ID: 10219074
    [No Abstract]   [Full Text] [Related]  

  • 4. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
    Penne EL; Neumann J; Klein IH; Oey PL; Bots ML; Blankestijn PJ
    J Nephrol; 2009; 22(2):208-15. PubMed ID: 19384838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of congestive heart failure. Has the time come for decreased complexity?
    Rydén L; Remme WJ
    Eur Heart J; 1999 Jun; 20(12):867-71. PubMed ID: 10329091
    [No Abstract]   [Full Text] [Related]  

  • 7. Sympathetic overactivity in renal failure controlled by ACE inhibition: clinical significance.
    Blankestijn PJ; Ligtenberg G; Klein IH; Koomans HA
    Nephrol Dial Transplant; 2000 Jun; 15(6):755-8. PubMed ID: 10831622
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.
    Ligtenberg G; Blankestijn PJ; Oey PL; Klein IH; Dijkhorst-Oei LT; Boomsma F; Wieneke GH; van Huffelen AC; Koomans HA
    N Engl J Med; 1999 Apr; 340(17):1321-8. PubMed ID: 10219067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sympathetic hyperactivity in chronic renal failure: a wake-up call.
    Koomans HA; Blankestijn PJ; Joles JA
    J Am Soc Nephrol; 2004 Mar; 15(3):524-37. PubMed ID: 14978154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sympathetic activation in chronic renal failure.
    Schlaich MP; Socratous F; Hennebry S; Eikelis N; Lambert EA; Straznicky N; Esler MD; Lambert GW
    J Am Soc Nephrol; 2009 May; 20(5):933-9. PubMed ID: 18799718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure?
    Remme WJ
    Heart Fail Clin; 2005 Apr; 1(1):67-75. PubMed ID: 17386835
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of chronic heart failure with angiotensin-converting enzyme inhibitors].
    Schofer J
    Dtsch Med Wochenschr; 1988 Oct; 113(43):1684-9. PubMed ID: 2846252
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
    Wang AY; Li PK; Lui SF; Sanderson JE
    Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
    Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
    Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carvedilol: the new role of beta blockers in congestive heart failure.
    Vanderhoff BT; Ruppel HM; Amsterdam PB
    Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cause and consequences of sympathetic hyperactivity in chronic kidney disease.
    Kotanko P
    Blood Purif; 2006; 24(1):95-9. PubMed ID: 16361848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Results of a randomised study].
    Latini R
    Ital Heart J Suppl; 2001 Jun; 2(6):692-3. PubMed ID: 11460849
    [No Abstract]   [Full Text] [Related]  

  • 19. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B; Habicht A
    Wien Med Wochenschr; 2004; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.